Jiangxi Jemincare Group Co. Ltd. and Shanghai Jemincare Pharmaceuticals Co. Ltd. have divulged tricyclic hypoxia inducible factor 2-alpha (HIF-2-alpha; EPAS1) inhibitors reported to be useful for the treatment of cancer, von Hippel-Lindau disease, pulmonary hypertension and inflammatory bowel disease.
Insilico Medicine IP Ltd. has described new TRAF2 and NCK-interacting protein kinase (TNIK) and/or mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4; HGK; MEKKK4) inhibitors reported to be useful for the treatment of cancer and fibrosis.
Medshine Discovery Inc. has patented substituted pyridine-2,4-dione derivatives acting as cardiac myosin inhibitors. As such, they are reported to be useful for the treatment of hypertrophic cardiomyopathy and heart failure.
F. Hoffmann-La Roche Ltd. has discovered benzothiazolyl bicyclo[1.1.1]pentane derivatives acting as hepatitis B virus (HBV) HBeAg and HBsAg secretion inhibitors, reported to be useful for the treatment of HBV infections.
Kashiv Biosciences LLC has synthesized prodrugs of azo compounds reported to be useful for the treatment of interstitial cystitis and pain, among other disorders.
Seecure Taiwan Co. Ltd. has disclosed compounds reported to be useful for the treatment or diagnosis of cancer, autoimmune diseases and atherosclerosis.
Medshine Discovery Inc. has described gonadotropin-releasing hormone receptor (GnRHR) antagonists reported to be useful for the treatment of prostate cancer.
Bayer AG has synthesized new furoindazole derivatives acting as G protein-coupled receptor 84 (GPR84) antagonists reported to be useful for the treatment of inflammation, metabolic disorders, autoimmune and lung diseases, among others.
Medshine Discovery Inc. has patented new sulfinylpyridine-containing nonreceptor tyrosine-protein kinase TYK2 inhibitors expected to be useful for the treatment of Crohn's disease, systemic lupus erythematosus, psoriasis, psoriatic arthritis and ulcerative colitis.
RSS
